Patents Assigned to Kite Pharma, Inc.
-
Patent number: 11357796Abstract: The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of determining an effective dose of a T cell immunotherapy comprising polyfunctional T cells prior to administration to the patient.Type: GrantFiled: April 3, 2018Date of Patent: June 14, 2022Assignee: KITE PHARMA, INC.Inventors: John M. Rossi, Adrian I. Bot
-
Publication number: 20220064596Abstract: Immune cell engineered to inhibit the endogenous expression of one or more of Blimp-1 and A20 and/or overexpress one or more of exogenous TCF7 and Bach2. Method of treating cancer, comprising administering the cells described herein. Method of increasing one or more of a peak fold proliferation rate, a killing efficiency, or inducing the cellular characteristics associated with naïve phenotype of an immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and Bach2. Method of generating a modified immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and B ach2.Type: ApplicationFiled: August 24, 2021Publication date: March 3, 2022Applicant: Kite Pharma, Inc.Inventors: Saikat Banerjee, Christopher Ecker, Yoonjung Shin
-
Patent number: 11129872Abstract: Provided herein are methods of making a detectably-labeled, soluble MHC molecule that can be used in a novel Kon-rate assay and an improved TCR ligand koff-rate assay.Type: GrantFiled: August 11, 2017Date of Patent: September 28, 2021Assignee: Kite Pharma, Inc.Inventor: Bianca Weissbrich
-
Patent number: 11046775Abstract: The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.Type: GrantFiled: February 14, 2018Date of Patent: June 29, 2021Assignee: Kite Pharma, Inc.Inventors: Ruben Alvarez Rodriguez, Armen Mardiros
-
Publication number: 20210163621Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.Type: ApplicationFiled: April 10, 2019Publication date: June 3, 2021Applicants: AMGEN INC., KiTe Pharma, Inc.Inventors: Michael John Giffin, Melissa THOMAS, Christopher MURAWSKY, Ryan B. CASE, Lawren WU, Jed J. WILTZIUS, Ruben Alvarez RODRIGUEZ, Jun FENG
-
Publication number: 20210023134Abstract: The disclosure provides a method of treatment of a B-cell lymphoma or leukemia, including diffuse large B-cell lymphoma (DLBCL) comprising a CD19-directed chimeric antigen receptor (CAR) genetically modified T-cell immunotherapy in combination with a 4-IBB (CD137) agonist. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T-cell therapy provided herein.Type: ApplicationFiled: January 15, 2019Publication date: January 28, 2021Applicants: Pfizer Inc., Kite Pharma, Inc.Inventors: William Y. GO, Adrian WOOLFSON
-
Patent number: 10844371Abstract: Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GGGS (SEQ ID NO: 1), GGGGS (SEQ ID NO: 46) and related sequences are provided. The antigen binding molecules may be used in the methods provided herein.Type: GrantFiled: September 21, 2018Date of Patent: November 24, 2020Assignee: Kite Pharma, Inc.Inventors: Jed J. W. Wiltzius, Stuart A. Sievers
-
Patent number: 10844120Abstract: The invention provides a humanized anti-CD19 antibody or antigen binding fragment thereof comprising a light chain variable (VL) region and a heavy chain variable (VH) region in which the humanized VL and VL regions are derived from the mouse anti-CD19 clone FMC63 antibody; the humanized VL and/or humanized VH region comprise one or more amino acid substitutions in the framework region. The humanized anti-CD19 antibody or antigen binding fragment may be part of a single chain variable fragment (scFv), a chimeric antigen receptor (CAR) or a T cell receptor (TCR). Other aspects of the invention relate to cells comprising the CAR or the TCR and their use in a T cell therapy.Type: GrantFiled: April 24, 2018Date of Patent: November 24, 2020Assignee: Kite Pharma, Inc.Inventors: Jed J. W. Wiltzius, Stuart A. Sievers
-
Patent number: 10689450Abstract: The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.Type: GrantFiled: March 31, 2017Date of Patent: June 23, 2020Assignee: KITE PHARMA, INCInventors: Jed Wiltzius, Ruben Alvarez Rodriguez, Jonathan Belk
-
Patent number: 10626187Abstract: Isolated antigen binding molecules that specifically bind to an anti-CD19 scFv comprising SEQ ID NO: 1 are provided. The antigen binding molecules can be used in the methods provided herein.Type: GrantFiled: September 27, 2017Date of Patent: April 21, 2020Assignee: Kite Pharma, Inc.Inventors: Jed Wiltzius, Stuart Sievers
-
Patent number: 10603380Abstract: The invention provides a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising extracellular domain disclosed herein. Some aspects of the invention relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising the extracellular domain disclosed herein. Other aspects of the invention relate to cells comprising the CAR or the TCR and their use in a T cell therapy.Type: GrantFiled: March 31, 2017Date of Patent: March 31, 2020Assignee: KITE PHARMA, INC.Inventor: Jed Wiltzius
-
Patent number: 10597456Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the antigen binding molecules and engineered immune cells.Type: GrantFiled: March 31, 2017Date of Patent: March 24, 2020Assignees: AMGEN INC., KITE PHARMA, INC.Inventors: Jed Wiltzius, Ruben Alvarez Rodriguez, Alice Bakker, Lawren Wu, Tara Arvedson
-
Patent number: 10501775Abstract: Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GSTSGSGKPGSGEGSTKG (SEQ ID NO: 1), GSGKPGSGEG (SEQ ID NO: 2), GKPGSGEG (SEQ ID NO: 3), SGKPGSGE (SEQ ID NO: 499) and KPGSG (SEQ ID NO: 500) are provided. The antigen binding molecules can be used in the methods provided herein.Type: GrantFiled: July 11, 2017Date of Patent: December 10, 2019Assignee: Kite Pharma, Inc.Inventors: Jed Wiltzius, Stuart Sievers, Arianne Perez Garcia
-
Publication number: 20190183931Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to FLT3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the FLT3 antigen binding molecules and engineered immune cells.Type: ApplicationFiled: March 31, 2017Publication date: June 20, 2019Applicants: AMGEN INC., KiTE Pharma, Inc.Inventors: BAKKER Alice, WU Lawren, ARVEDSON Tara, WILTZIUS J. Jed, RODRIGUEZ Alvarez Ruben
-
Patent number: 10322146Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: GrantFiled: July 13, 2017Date of Patent: June 18, 2019Assignees: Kite Pharma, Inc., The United States of America as Represented by the Secretary, Department of Health and Human ServicesInventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
-
Publication number: 20180369283Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: ApplicationFiled: April 10, 2018Publication date: December 27, 2018Applicants: Kite Pharma, Inc., United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
-
Publication number: 20180344767Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.Type: ApplicationFiled: May 27, 2016Publication date: December 6, 2018Applicants: Kite Pharma, Inc., The United States of America as represented by the Secretary Department of Health and Human ServicesInventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
-
Patent number: 9855298Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: GrantFiled: May 27, 2016Date of Patent: January 2, 2018Assignees: Kite Pharma, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
-
Publication number: 20170368101Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: ApplicationFiled: July 13, 2017Publication date: December 28, 2017Applicants: Kite Pharma, Inc., United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
-
Publication number: 20170136063Abstract: Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.Type: ApplicationFiled: October 20, 2016Publication date: May 18, 2017Applicants: Kite Pharma, Inc., National Cancer InstituteInventors: Arianne Perez, Marianna Sabatino, Steven A. Rosenberg, Nicholas P. Restifo